title: Inhibition of Factor XI activity as a promising antithrombotic strategy.
abstract: Prevention and treatment of thromboembolic disorders with minimal bleeding risk remains a significant unmet medical need. Studies in Factor XI (FXI)-deficient humans and experimental animal models suggest that targeting FXI in humans provides antithrombotic benefits with reduced bleeding liability compared with current standard of care. In this review, we describe an exciting era in the discovery and development of antithrombotic agents as multiple therapeutic modalities for FXI(a) inhibition progress through preclinical and clinical development.
authors.affiliation: Merck Research Laboratories, Cardiometabolic Disease Biology, 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA.
authors.forename: Zhu
authors.initials: Z
authors.lastname: Chen
authors.affiliation: Merck Research Laboratories, Cardiometabolic Disease Biology, 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: dietmar.seiffert@merck.com.
authors.forename: Dietmar
authors.initials: D
authors.lastname: Seiffert
authors.affiliation: Merck Research Laboratories, Cardiometabolic Disease Biology, 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Hawes
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D015195:Drug Design; D055808:Drug Discovery / Q000379:methods; D005172:Factor XI / Q000037:antagonists & inhibitors*; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D013923:Thromboembolism / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D005343:Fibrinolytic Agents; D005172:Factor XI